As the curtain rises on the drug industry's latest act, the scene is ominous. Executives must choose a strategic course in the face of shifting industry economics. This will not be easy.
Adcock Ingram of South Africa has announced its intention to acquire the entire issued ordinary share capital of Cipla Medpro South Africa (CMSA) for a consideration of $228 million (2.125 billion rand). At 4.75 rand per share, this represents a premium of 36 per cent to CMSA’s closing share price on April 7.